TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36922777
Drug: 10 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 µg of vitamin D supplementation
Study: 36922785
Drug: Cilofexor 100
Normalized name: Cilofexor
DrugBank: Cilofexor (DB15168)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilofexor 100 mg once daily for up to 96 weeks
Study: 36922785
Drug: Cilofexor 100
Normalized name: Cilofexor
DrugBank: Cilofexor (DB15168)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilofexor 100 mg daily (open-label) after the blinded phase
Study: 36922805
Drug: Neoadjuvant chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemoradiotherapy (41.4 Gy with 23 fractions) with concurrent chemotherapy (albumin-bound paclitaxel, 100 mg/m2) followed by tislelizumab.
Study: 36922871
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of both interventions (online risk-reduction intervention and HCV-RNA self-sampling)
Study: 36922936
Drug: ZL-1211 (anti-CLDN18.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZL-1211 (anti-CLDN18.2 therapeutic antibody)
Study: 36922962
Drug: Guided internet-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guided internet-based intervention for procrastination; details on dosage and duration not available.
Study: 36923108
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart one to three times daily
Study: 36923108
Drug: Insulin aspart
Normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin aspart three times daily with insulin detemir once daily
Study: 36923108
Drug: Insulin detemir
Normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Insulin detemir once daily
Study: 36923305
Drug: Mavorixafor monotherapy
Normalized name: Mavorixafor
DrugBank: Mavorixafor (DB05501)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mavorixafor monotherapy
Study: 36923305
Drug: Mavorixafor in
Normalized name: Mavorixafor
DrugBank: Mavorixafor (DB05501)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mavorixafor in combination with pembrolizumab
Study: 36923307
Drug: Pelabresib (CPI-0610)
Normalized name: pelabresib
DrugBank: Pelabresib anhydrous (DB17129)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelabresib (CPI-0610) 225 mg tablet daily
Study: 36923454
Drug: Zilucoplan (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zilucoplan (0.3 mg/kg daily subcutaneous)
Study: 36923571
Drug: AV-101 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: AV-101 (1 mg, 3 mg, 10 mg, 30 mg, 90 mg)
Study: 36923571
Drug: AV-101 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: AV-101 (10 mg, 30 mg, 90 mg)
Study: 36923571
Drug: Oral imatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral imatinib (400 mg)
Study: 36924249
Drug: Platelet therapy
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet therapy
Study: 36924936
Drug: HDM SLIT-tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDM SLIT-tablet (12 SQ-HDM dose)
Study: 36925176
Drug: Azithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin (500 mg taken once per day for 3 days)
Study: 36925176
Drug: Amoxicillin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (1 g taken three times per day for 5 days)
Study: 36925176
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (no immediate antibiotics)
Study: 36925176
Drug: All groups
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All groups (standard of care, azithromycin, amoxicillin)
Study: 36925644
Drug: Vidutolimod, Atezolizumab,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vidutolimod, Atezolizumab, and Radiation Therapy (Part B)
Study: 36927054
Drug: Sensor-Augmented Pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sensor-Augmented Pump Therapy
Study: 36927366
Drug: Galcanezumab treatment
Normalized name: Galcanezumab
DrugBank: Galcanezumab (DB14042)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Galcanezumab treatment for 3 months
Study: 36927409
Drug: Lumbar traction
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbar traction therapy (30 min a day, continuous mode with a force level of 25-30% of body weight) in normal-weight group
Study: 36927409
Drug: Lumbar traction
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lumbar traction therapy (30 min a day, continuous mode with a force level of 25-30% of body weight) in obesity group
Study: 36927419
Drug: Standard-dose CT-guided
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose CT-guided biopsy
Study: 36927420
Drug: Canocapavir 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canocapavir 50 mg
Study: 36927420
Drug: Canocapavir 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canocapavir 100 mg
Study: 36927420
Drug: Canocapavir 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canocapavir 200 mg
Study: 36927455
Drug: Intravenous Interferon
Normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous Interferon beta-1a (IFN β-1a)
Study: 36927458
Drug: MiniMed™ 780G
Approvals — FDA: no, EMA: no, PMDA: no
Description: MiniMed™ 780G hybrid closed-loop (HCL) insulin delivery system
Study: 36927458
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (SoC) - continuation of current T1D treatment with multiple daily injections (MDI) or continuous subcutaneous insulin infusion (CSII) and any type of CGM
Study: 36927462
Drug: UMGI capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: UMGI capsule endoscopy
Study: 36927527
Drug: GSK3174998 (0.003-10
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3174998 (0.003-10 mg/kg)
Study: 36927527
Drug: GSK3174998 (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3174998 (0.3 mg/kg)
Study: 36927585
Drug: Capecitabine plus
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine plus oxaliplatin (CAPOX) chemotherapy, tislelizumab, and preoperative split-course hypofraction radiotherapy (SCHR) (5×7 Gy)
Study: 36927754
Drug: Intense exercise
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intense exercise and exposure to air pollution (specific dosage and duration not mentioned)
Study: 36928238
Drug: Transdiagnostic group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdiagnostic group cognitive-behavioural therapy (TD-CBT) plus treatment as usual (TAU)
Study: 36928238
Drug: Clinical symptoms,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical symptoms, quality of life (QoL), functioning, and treatment satisfaction
Study: 36928313
Drug: Bilateral single-shot
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bilateral single-shot ESPB with a local anesthetic mixture of 10 mL 0.5% bupivacaine, 5 mL 2% lidocaine, and 5 mL saline
Study: 36928395
Drug: Allogeneic bone
Normalized name: Human allogeneic bone marrow derived osteoblastic cells
DrugBank: Human allogeneic bone marrow derived osteoblastic cells (DB17890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic bone marrow-derived mesenchymal stromal cells (alloBM-MSCs) infusion
Study: 36928527
Drug: Pembrolizumab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab (200 mg intravenously on day 1) added to ICE chemotherapy (ifosfamide, carboplatin, etoposide) every 21 days for 2 cycles, followed by 1 cycle of pembrolizumab monotherapy.
Study: 39086130
Drug: Filgotinib 200
Normalized name: nilotinib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Filgotinib 200 mg (FIL200)
Study: 36928818
Drug: Nivolumab +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab + chemotherapy (Nivo+CT)
Study: 36928818
Drug: Ipilimumab +
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab + nivolumab + chemotherapy (Ipi+Nivo+CT)
Study: 36928818
Drug: Nivolumab +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab + chemotherapy (Nivo+CT) in patients without known tumor EGFR/ALK alterations
Study: 36928818
Drug: Ipilimumab +
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab + nivolumab + chemotherapy (Ipi+Nivo+CT) in patients without known tumor EGFR/ALK alterations
Study: 36929216
Drug: 10-µg BNT162b2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-µg BNT162b2 vaccine dose
Study: 36929533
Drug: Intramuscular JZP458
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular JZP458 (recombinant Erwinia chrysanthemi asparaginase)
Study: 36931078
Drug: Q6W dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q6W dosing of natalizumab (300 mg every 6 weeks)
Study: 36931078
Drug: Q4W dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Q4W dosing of natalizumab (300 mg every 4 weeks)
Study: 36931261
Drug: Assisted oocyte
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assisted oocyte activation (AOA) using CaCl2 injection and double ionomycin exposure
Study: 36931398
Drug: Absolute iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Absolute iron deficiency (S-Ferritin<100 μg/L)
Study: 36931680
Drug: Antenatal corticosteroids
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antenatal corticosteroids (CCS) administration
Study: 36931755
Drug: Problem-solving therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Problem-solving therapy (PST) over 2 months
Study: 36931805
Drug: Pitolisant (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitolisant (5 mg to 40 mg daily for 4 weeks)
Study: 36931829
Drug: Brief family-involved
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brief family-involved treatment (B-FIT)
Study: 36932165
Drug: Donor-derived natural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donor-derived natural killer cell infusion (DNKI)
Study: 36932262
Drug: 2-h pre-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-h pre-dose fast followed by a 30-min post-dose fast (2 h-30 min)
Study: 36932262
Drug: 4-h pre-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-h pre-dose fast followed by a 30-min post-dose fast (4 h-30 min)
Study: 36932262
Drug: 6-h pre-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-h pre-dose fast followed by a 30-min post-dose fast (6 h-30 min)
Study: 36932262
Drug: 2-h pre-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-h pre-dose fast followed by an overnight post-dose fast (2 h-night)
Study: 36932262
Drug: Overnight pre-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overnight pre-dose fast followed by a 30-min post-dose fast (night-30 min)
Study: 36932346
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of MMR and YF vaccines
Study: 36932714
Drug: Direct oral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct oral anticoagulants (DOACs) management with interruption 52 (IQR 37-62) hours before the procedure and resumption 31 (IQR 21-47) hours later.
Study: 36932714
Drug: Direct oral
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct oral anticoagulants (DOACs) management with interruption and high CHA2DS2-VASc score.
Study: 36933080
Drug: High exposure
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High exposure to anticholinergic and sedative medications (DBI ≥ 1)
Study: 36933080
Drug: Low exposure
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low exposure to anticholinergic and sedative medications (0 < DBI < 1)
Study: 36933080
Drug: No exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: No exposure to anticholinergic and sedative medications (DBI = 0)
Study: 36933101
Drug: Control condition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control condition (treatment as usual).
Study: 36934202
Drug: Deep-learning-based contrast-boosting
Normalized name: Deep Sea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deep-learning-based contrast-boosting algorithm on double-low-dose CT (DLD-DL)
Study: 36934202
Drug: Standard-dose CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose CT (SD)
Study: 36934257
Drug: Guadecitabine in
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Guadecitabine in combination with ICBs (anti-CTLA-4 and anti-PD-1)
Study: 36934327
Drug: First-line Infliximab
Normalized name: Infliximab
DrugBank: Infliximab (DB00065)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: First-line Infliximab (FL-IFX), five 5-mg/kg infusions over 22 weeks
Study: 36934327
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (CONV), exclusive enteral nutrition or oral prednisolone
Study: 36934366
Drug: Danavorexton (TAK-925)
Normalized name: Danavorexton
DrugBank: Danavorexton (DB16962)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Danavorexton (TAK-925) 0.1 mg/kg
Study: 36934668
Drug: Propolis (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propolis (400 mg/day) for two months
Study: 36934668
Drug: Placebo (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (400 mg/day) for two months
Study: 36934733
Drug: MV-LASV (low-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: MV-LASV (low-dose group)
Study: 36934733
Drug: MV-LASV (high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: MV-LASV (high-dose group)
Study: 36934740
Drug: Semaglutide 2·4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semaglutide 2·4 mg once weekly
Study: 36934894
Drug: Adaptive planning
Normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Adaptive planning following initial treatment plans
Study: 36935024
Drug: Low-dose whole
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose whole brain radiation therapy (LD-WBRT) at 2 Gy × 5 over 1 week
Study: 36936230
Drug: Radspherin® administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radspherin® administered intraperitoneally 2 days after CRS-HIPEC; dose escalation at 1-2-4-7 MBq; evaluated for safety and tolerability.
Study: 36936402
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g C19-IG20%
Study: 36936402
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g C19-IG20%
Study: 36936523
Drug: Self-directed home
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-directed home therapy adherence combined with TheraBracelet (subsensory random-frequency vibratory stimulation)
Study: 36936918
Drug: SARS-CoV-2-specific antiviral
Normalized name: SARS-COV
Approvals — FDA: no, EMA: no, PMDA: no
Description: SARS-CoV-2-specific antiviral immunity transfer from HCT donors (vaccinated or with a history of COVID-19)
Study: 36936952
Drug: 3-month interval
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 3-month interval between second and third doses of COVID-19 vaccine
Study: 36936952
Drug: 5-month interval
Normalized name: moth bean
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-month interval between second and third doses of COVID-19 vaccine
Study: 36938985
Drug: Single-shot caudal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-shot caudal anaesthesia with 0.8 ml kg -1 of 2 mg kg -1 bupivacaine solution (group L, n = 29)
Study: 36938985
Drug: Single-shot caudal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-shot caudal anaesthesia with 1.25 ml kg -1 of 2 mg kg -1 bupivacaine solution (group H, n = 29)
Study: 36939601
Drug: Electronic memory
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Electronic memory and management aid (EMMA) tablet application
Study: 36939629
Drug: Tesnatilimab 400
Normalized name: Tesnatilimab
DrugBank: Tesnatilimab (DB16377)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tesnatilimab 400 mg SC
Study: 36939629
Drug: Tesnatilimab 50
Normalized name: Tesnatilimab
DrugBank: Tesnatilimab (DB16377)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tesnatilimab 50 mg, 150 mg, 400 mg SC
Study: 36939629
Drug: Ustekinumab ~6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab ~6 mg/kg IV at Week 0 and 90 mg SC at Weeks 8 and 16
Study: 36939801
Drug: sEH inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: sEH inhibitors
Study: 36939832
Drug: Ivermectin MDA
Normalized name: Ivermectin
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin MDA at 300 μg/kg for 3 consecutive days, provided under supervision to all eligible village inhabitants, over 2 successive rainy seasons.
Study: 36940069
Drug: Rivaroxaban (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (20 mg once daily or 15 mg if creatinine clearance was between 30 and 49 mL/min)
Study: 36940437
Drug: 14-day high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day high-dose dual therapy
Study: 38500841
Drug: 10-day bismuth
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day bismuth quadruple therapy
Study: 36940444
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg of apixaban twice daily for 30 days
Study: 36940444
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg of apixaban
Study: 36941030
Drug: High-flow (HF)
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow (HF) oxygen therapy at flow rates of 2 L/kg for the first 10 kg, plus 0.5 L/kg for every kg >10 kg
Study: 36941030
Drug: Low-flow (LF)
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-flow (LF) oxygen therapy with a maximum flow rate of 3 L/min
Study: 36941030
Drug: Low-flow (LF)
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-flow (LF) oxygen therapy
Study: 36941030
Drug: High-flow (HF)
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow (HF) oxygen therapy
Study: 36941133
Drug: BDG threshold
Approvals — FDA: no, EMA: no, PMDA: no
Description: BDG threshold of 125 pg/mL
Study: 36941155
Drug: M-001 (1.0-mg)
Normalized name: M
Approvals — FDA: no, EMA: no, PMDA: no
Description: M-001 (1.0-mg)
Study: 36941575
Drug: ctDNA-guided chemotherapy
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ctDNA-guided chemotherapy
Study: 36942507
Drug: ASP1128 single
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP1128 single dose (0.3-10 mg)
Study: 36942507
Drug: ASP1128 multiple
Approvals — FDA: no, EMA: no, PMDA: no
Description: ASP1128 multiple dose (3-100 mg)
Study: 36942533
Drug: 4F-PCC (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4F-PCC (1 mL/kg, 25 IU of factor IX/kg)
Study: 36942533
Drug: Placebo (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (1 mL/kg saline solution)
Study: 36942789
Drug: Intravenous hydrocortisone
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intravenous hydrocortisone (200 mg daily for either 4 or 7 days, followed by tapering for a total of 8 or 14 days)
Study: 36942937
Drug: Ixazomib, oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixazomib, oral metronomic cyclophosphamide, and dexamethasone
Study: 36943437
Drug: Motor evoked
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Motor evoked potentials (MEPs) measured twice, 2 weeks apart, every 6 months.
Study: 36944059
Drug: Basal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal insulin Fc (BIF) once weekly
Study: 36944059
Drug: Insulin Degludec
Normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Insulin Degludec once daily
Study: 36944128
Drug: Ultrasound-Guided Transcutaneous
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-Guided Transcutaneous Injection in the Lacrimal Gland
Study: 36944142
Drug: Drug/LA group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug/LA group (laser acupuncture therapy for 20 minutes per session, three sessions weekly, plus calcium and vitamin D 3 supplement containing fluoride)
Study: 36944142
Drug: Drug-only group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug-only group (calcium and vitamin D 3 supplement containing fluoride)
Study: 36944461
Drug: Heparin-only lock
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-only lock solution
Study: 36944463
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose infusion of low-molecular weight iron dextran (1000 mg)
Study: 36945146
Drug: Fully digital
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fully digital continuous self-screening for AF using a patch ECG device (ECG247 Smart Heart Sensor)
Study: 36945217
Drug: Drug-responsive phenomic
Normalized name: Phenol
DrugBank: Phenol (DB03255)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Drug-responsive phenomic alteration-related driver genes (PARGs) identified in the XYZ phenome
Study: 36945475
Drug: Reduced lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reduced lipid emulsion dosing
Study: 36945475
Drug: Usual lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual lipid emulsion dosing
Study: 36945495
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care intravenous cytotoxic chemotherapy
Study: 37608471
Drug: Canagliflozin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Canagliflozin (300 mg)
Study: 39252484
Drug: Gaze-contingent music
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gaze-contingent music reward therapy (GC-MRT)
Study: 36945997
Drug: Topical lavender
Normalized name: LAVENDER
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical lavender oil
Study: 36946232
Drug: High-Dose Prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Dose Prophylactic Anticoagulation (HD-PA)
Study: 36946232
Drug: Standard-Dose Prophylactic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-Dose Prophylactic Anticoagulation (SD-PA)